Steve Moore

The CEO of MyCelx Technologies (MYX) Connie Mixon states that “the first half of 2026 demonstrates continued progress in our strategy to build the MYCELX brand as the global standard for onshore and offshore produced water treatment”. I though most recently wrote on the company in July, ‘states “continues to manage its working capital to support its future growth ambitions”, it means because otherwise it's cash crunch ahoy?' . So what's the half-year results detail in the context of the valuation at an around 50p share price?

Describing itself as a “UK pioneer in solid-state battery technology”, Ilika (IKA) has announced “Goliath Prototyping Progress” emphasising “a successful outcome to its grant-supported PRIMED programme to optimise the performance of its Goliath 10Ah prototypes” . How significant is this currently in the context of the valuation at a 23.5p share price?

UK wealth management group Brooks Macdonald (BRK) has announced its year ended 30th June 2026 results and that it presently anticipates current year financial performance “marginally ahead of current market expectations”. How do the latest results and outlook compare to the valuation at a 1555p share price?

Textile rental and related services group Johnson Service (JSG) has announced its results for the first half of 2026 along with “expect to deliver another year of progress” . How do the results and outlook compare to the valuation at a current 134p share price?

A week ago I wrote on Fiinu plc (BANK) ‘“Operational Update”, why might this be timely for an attempted ramptastic?', concluding, with the shares a bit up from the prior close 3.75p, still a sell . It is today “delighted that shareholders have chosen to support the board and vote against the resolutions proposed by the requisitioning shareholder” and has also announced first half of 2026 results.

Most recently on ‘high performance polymers' company Victrex (VCT), in July with the shares rising above 650p on a positive trading statement we concluded including that there looked clear profit upside potential and a recovery and income Buy. What of now a “Pre-Close Trading Update” and the shares at 985p?

Nasdaq-listed Circle8 Group has issued a “Statement re Possible Offer” for international ‘Science, Technology, Engineering and Mathematics' staffing company SThree (STEM), noting that it “has submitted a proposal to acquire… SThree in a possible cash offer”. And what about now also a rejection announcement by SThree?

Most recently on company describing itself as a “leading data, insight, and technology company” GlobalData (DATA), in July with the shares further down to around 75p I reviewed ‘how's its previously-argued “Primed for Growth in AI Age” going?', concluding ‘with the latest stated with “a challenging macro-economic backdrop in which sales cycles have elongated industry wide” - but isn't AI booming, and it “Primed for Growth in AI Age”? - at least ahead of 14th September-scheduled results and ‘growth plan' detail, still avoid' . The shares most recently closed at 71.6p and now the results headlined “Resilient H1 performance and strategic evolution to drive long-term value creation”… and so what of the shares currently falling below 60p?

Most recently on ‘billing, charging and customer relationship management software' company Cerillion (CER), at the start of June with the shares falling below 1400p I wrote ‘interims, is it really “on track to deliver FY26 financial targets”?' concluding that with ‘macro environment volatility, I suggest it's good luck with the second half playing out exactly as hoped and that the prospective earnings multiple even on that means precious little valuation margin of safety. As such, at least ahead of a further trading update, I retain prior caution and still a sell' . The shares most recently closed at 885p and what of now a “Full Year Trading Update”… and the shares currently falling below 800p?

‘Specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications', Fusion Antibodies (FAB) has announced results for its year ended 31st March 2026 including “another year of important progress for the company. We had revenue growth, a significant improvement in gross margin and a stronger cash position… Scientifically, we have continued to make excellent progress” . However, why has it not announced the results until now? – and I note I previously wrote on the company in May; ‘Japan patent grant, “excellent news” or rather attempted ramptastic?'